News

So far Boehringer Ingelheim has paid totalling up to €12m in milestone payments as part of this agreement. Reportedly, the agreement will allow potential milestone payments of up

The illumigene molecular amplification assay detects the presence of the toxin producing region from the C difficile DNA, and provides accurate results in under an hour. Meridian claims

Discovered by Aveo Pharma through its Human Response Platform, AV-299 is a functional anti-HGF antibody. The Phase 1 clinical trials of AV-299 demonstrated a favorable tolerability profile and

The study programme follows pre-clinical research results and comprises at least three small scale clinical trials evaluating various metabolic parameters. The first Phase IIa study to commence is

The FDA’s Neutroval CRL is for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for

Results from the Phase III study showed that Lixisenatide once-daily in combination with basal insulin (with or without sulfonylurea) significantly improved glycemic control. Sanofi-aventis R&D executive vice president

The DispersinB topical wound spray was manufactured by Therapure Biopharma (Mississauga, ON, Canada), under current Good Manufacturing Practices (cGMP). DispersinB is an antibiofilm enzyme, which inhibits and disperses

The base award is valued at $5.4m over 17 months; with provisions for renewal at the NCI’s option. The contract is partly funded by the American Recovery and

Boehringer, with its new production facility, is doubling its annual production capacity to 20 million inhalation devices (Respimat Soft Mist Inhaler). The expansion also involves the creation of